See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

The U.S. Food and Drug Administration issued its first formal guidance on how to design and run clinical trials for psychedelic drugs, a move that directly clears a path for psilocybin, the active ...

Ever wonder what it’s like to drive a streetcar during one of New Orleans’ most chaotic times of year? Go behind the scenes with a driver whose been doing it for more than a decade. “You never know ...

Psilocybin is being studied in controlled trials for depression and PTSD, with some promising early results. But these ...

A Phase IIa clinical trial finds that a single, brief dose of DMT (from ayahuasca) provides rapid and lasting relief for depression.

Author Jill Aster launches the Riftborn Series with a high-stakes epic where power, prophecy, and slow-burn romance ...

The drug – called SPL026 – was originally developed by UK firm Small Pharma, which was acquired by Canadian firm Cybin in ...

The Florida theme park claims that the incident was the result of the woman’s own negligence and she needed "to use reasonable care for her own safety.” ...

For years, social media companies have disputed allegations that they harm children’s mental health through deliberate design ...

Homicide victim Marchello D. Woodard's two oldest children, Malakai, 23, and Mekhia,18, are graduating from school without ...